Hangzhou Bio-Sincerity Pharma-Tech News

Baicheng Pharmaceutical (301096): New orders are growing steadily, and the share of self-developed technology transformation is increasing

Aug 23 11:16

Baicheng Pharmaceutical (301096): Entrusted R&D is under pressure, self-development transformation has begun to accelerate

Aug 21 00:00

Baicheng Pharmaceutical (301096): 2024 Interim Report Review: Independent Achievement Transformation High Contribution Trusteeship Service Fluctuates

Aug 20 07:56

Baicheng Pharmaceutical (301096): Rapid growth in technological transformation, acceleration of transformation and upgrading

Aug 20 00:00

Baicheng Pharmaceutical (301096) Company Information Update Report: Steady Growth in Revenue and Orders Increase New Growth Points in R&D

Aug 18 00:00

Baicheng Pharmaceutical (301096): Self-development converted to high growth, and the growth of new orders was relatively steady

Aug 17 13:36

Baicheng Pharmaceutical (301096): Self-development and transformation business continues to grow at a high rate to transform the development of new drugs and difficult to generic drugs

Aug 16 20:16

Baicheng Pharmaceutical (301096): Steady growth in main business, rapid increase in R&D investment

Aug 14 00:00

Baicheng Pharmaceutical (301096): Imitate CRO industry leader in multi-field layout to drive long-term development

Jun 10 00:00

Baicheng Pharmaceutical (301096): Performance is in line with expectations, new signings maintain high growth

May 14 07:36

Baicheng Pharmaceutical (301096): Profit side performance in the first quarter exceeded expectations, and orders continued to grow rapidly

May 10 00:00

Baicheng Pharmaceutical (301096): Revenue increased 68% in 2023, new orders increased rapidly

May 6 13:11

Baicheng Pharmaceutical (301096): Continued high growth in performance and collaborative development of various businesses

Apr 29 13:26

Baicheng Pharmaceutical (301096): New orders maintain high growth, optimistic that high growth will continue

Apr 28 07:42

Baicheng Pharmaceutical (301096): Performance is in line with expectations, and on-hand orders are growing steadily

Apr 25 18:16

Baicheng Pharmaceutical (301096): Order revenue maintains a high growth rate and leads the generic drug CRO business

Apr 25 14:06

Baicheng Pharmaceutical (301096): Continued high cashout, optimistic that high growth will continue

Apr 24 18:32

Donghai Securities released a research report on April 24 stating that Baicheng Pharmaceutical (301096.SZ) was given a purchase rating. The main reasons for the rating include: 1) continued high growth in performance; 2) abundant orders and staff expansio

Zhitong FinanceApr 24 12:35

Pacific released a research report on April 24 stating that Baicheng Pharmaceutical (301096.SZ) was given a purchase rating. The main reasons for the rating include: 1) the annual growth rate of clinical and CDMO, and the 23Q4 performance achieved rapid g

Zhitong FinanceApr 24 10:52

Baicheng Pharmaceutical (301096): The main business continues to be strong, and various business highlights are frequent

Apr 24 00:00